Infliximab in ulcerative colitis
Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, place...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2008
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721383/ |
| id |
pubmed-2721383 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-27213832009-08-25 Infliximab in ulcerative colitis Levin, Avi Shibolet, Oren Review Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC. Dove Medical Press 2008-09 2008-09 /pmc/articles/PMC2721383/ /pubmed/19707369 Text en © 2008 Dove Medical Press Limited. All rights reserved |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Levin, Avi Shibolet, Oren |
| spellingShingle |
Levin, Avi Shibolet, Oren Infliximab in ulcerative colitis |
| author_facet |
Levin, Avi Shibolet, Oren |
| author_sort |
Levin, Avi |
| title |
Infliximab in ulcerative colitis |
| title_short |
Infliximab in ulcerative colitis |
| title_full |
Infliximab in ulcerative colitis |
| title_fullStr |
Infliximab in ulcerative colitis |
| title_full_unstemmed |
Infliximab in ulcerative colitis |
| title_sort |
infliximab in ulcerative colitis |
| description |
Infliximab, a monoclonal anti-TNF-α antibody, is commonly used for treatment of moderate to severe Crohn’s disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-α in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews that assess the efficacy of infliximab in the treatment of moderate to severe UC. |
| publisher |
Dove Medical Press |
| publishDate |
2008 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721383/ |
| _version_ |
1611440784776626176 |